期刊文献+

优思弗治疗原发性胆汁性肝硬化的疗效观察 被引量:7

下载PDF
导出
摘要 目的:分析熊去氧胆酸治疗原发性胆汁性肝硬化的疗效,旨在提高对该病的治疗水平。方法:将临床、病理学诊断原发性胆汁性肝硬化的30例住院患者随机分为两组,总结应用熊去氧胆酸治疗组与对照组的患者治疗前后的临床特征、各项生化等指标并进行统计学分析。结果:30例患者治疗前两组肝功能无明显差异。治疗组在治疗前后ALT、AST、TBil、ALP、GGT存在差异,对照组在治疗前后ALT、AST、TBil存在差异,两组治疗后肝功能比较,TBil、GGT存在差异。临床分析,治疗后16例治疗组中10例患者显效,5例患者有效,总有效率98.3%;而对照组14例中,4例显效,5例有效,总有效率64.3%,两组病例治疗后有明显的统计学意义。在治疗过程中患者耐受性好,未见明显不良反应。结论:熊去氧胆酸可明显改善PBC患者的临床症状和肝功能生化指标,且其不良反应较小,是目前治疗PBC的首选药物。
出处 《实用临床医学(江西)》 CAS 2006年第10期59-60,共2页 Practical Clinical Medicine
  • 相关文献

参考文献6

  • 1Metcalf JV,Mitchison HC,Palmer JM,et al.Natural history of early primary biliary cirrhosis[J].Lancet.1996 348(9039):1399-402.
  • 2Heathcote EJ.Management of primary biliary cirrhosis.The American Association for the Study of Liver Diseases practice guidelines[J].Hepatology,2000,31(4):1005-1013.
  • 3Jorgensen R,Angulo P,Dickson ER,et al.Results of long-term ursodiol treatment for patients with primary biliary cirrhosis[J].Am J Gastroenterol,2002,97(10):2647-2650.
  • 4Roda E,Azzaroli F,Nigro G,Piazza F,et al.Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis[J].Dig Liver Dis,2002,34(7):523-527.
  • 5Leuschner M,Holtmeier J,Ackermann H,et al.The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid:a pilot study[J].Eur J Gastroenterol Hepatol,2002,14(12):1369-1376.
  • 6Papatheodoridis GV,Hadziyannis ES,Deutsch M,et al.Ursodeoxycholic acid for primary biliary cirrhosis:final results of a 12-year,prospective,randomized,controlled trial[J].Am J Gastroenterol,2002,97(8):2063-2070.

同被引文献32

  • 1施健,刘苏,陈伟忠,曾欣,陈岳祥,杨秀疆,谢渭芬.中等剂量熊去氧胆酸治疗原发性胆汁性肝硬化的系统评价[J].中华消化杂志,2005,25(6):355-358. 被引量:30
  • 2周建方.熊去氧胆酸治疗原发性胆汁性肝硬化临床观察[J].浙江实用医学,2006,11(4):246-247. 被引量:3
  • 3黄峰,戴侃记,孙晓洁.补阳还五汤加味治疗原发性胆汁性肝硬化30例[J].陕西中医学院学报,2006,29(5):39-41. 被引量:19
  • 4胡晓平.扶正化瘀胶囊对肝硬化失代偿期的临床疗效[J].现代中西医结合杂志,2007,16(15):2038-2039. 被引量:4
  • 5Heathcote EJ.Management of primary biliary cirrhosis:theAmerican Association for the Study of Liver Disease practiceguidelines.Hepatology,2000,31(4):1005-1013.
  • 6Poupon RE,Bonnand AM,Chretien Y,et al.Ten-year surviv-al in ursodeoxycholic acid-treated patients with primary biliar-y cirrhosis:the UDCA-PBC Study Group.Hepatology,1999,29(6):1668-1671.
  • 7Lazaridis KN,Gores GJ,Lindor KD.Ursodexycholic acid me-chanisms of action and clinical use in hepatobiliary disorders.J Hepatol,2001,35(1):134-146.
  • 8Poupon R,Poupon RE.Treatment of primary biliary cirrho-sis.Baillieres Best Pract Res Clin Gastroenterol,2000,14(4):615-628.
  • 9Prince M,Chetwynd A,Newman W,et al.Survival and symp-tom progression in a geographically based cohort of patientswith primary biliary cirrhosis:follow-up for up to 28years.Gastroenterology,2002,123(4):1044-1051.
  • 10Jorgensen R,Angulo P,Dickson R,et al.Results of long-term ursodiol treatment for patients with primary biliary cir-rhosis.Am Gastroenterol,2002,97(10):2647-2650.

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部